Cargando…

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples

BACKGROUND: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, David J, Nunez, Maria I, Jelinek, Jaroslav, Hong, David, Gupta, Sanjay, Aldaz, Marcelo, Issa, Jean-Pierre, Kurzrock, Razelle, Wistuba, Ignacio I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094901/
https://www.ncbi.nlm.nih.gov/pubmed/25024751
http://dx.doi.org/10.1186/1868-7083-6-13
_version_ 1782325918008606720
author Stewart, David J
Nunez, Maria I
Jelinek, Jaroslav
Hong, David
Gupta, Sanjay
Aldaz, Marcelo
Issa, Jean-Pierre
Kurzrock, Razelle
Wistuba, Ignacio I
author_facet Stewart, David J
Nunez, Maria I
Jelinek, Jaroslav
Hong, David
Gupta, Sanjay
Aldaz, Marcelo
Issa, Jean-Pierre
Kurzrock, Razelle
Wistuba, Ignacio I
author_sort Stewart, David J
collection PubMed
description BACKGROUND: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTEN), immunohistochemistry scores from pre- and post-decitabine tumor biopsies (25 patients) were correlated with methylation of the long interspersed nuclear element-1 (LINE-1) repetitive DNA element (as a surrogate for global DNA methylation) and with tumor regression. RESULTS: With negative staining pre-decitabine (score = 0), the number of patients converting to positive staining post-decitabine was 1 of 1 for FHIT, 3 of 6 for WWOX, 2 of 3 for FUS1 and 1 of 10 for PTEN. In tumors with low pre-decitabine tumor suppressor gene scores (≤150), expression was higher post-treatment in 8 of 8 cases for FHIT (P = 0.014), 7 of 17 for WWOX (P = 0.0547), 7 of 12 for FUS1 (P = 0.0726), and 1 of 16 for PTEN (P = 0.2034). If FHIT, WWOX and FUS1 were considered together, median pre- versus post-decitabine scores were 60 versus 100 (P = 0.0002). Overall, tumor suppressor gene expression change did not correlate with LINE-1 demethylation, although tumors converting from negative to positive had a median decrease in LINE-1 methylation of 24%, compared to 6% in those not converting (P = 0.069). Five of 15 fully evaluable patients had reductions in tumor diameter (range 0.2% to 33.4%). Of these, three had simultaneous increases in three tumor suppressor genes (including the two patients with the greatest tumor regression) compared to 2 of 10 with tumor growth (P = 0.25). CONCLUSIONS: In tumors with low tumor suppressor gene expression, decitabine may be associated with increased expression of the tumor suppressor genes FHIT, FUS1, and WWOX, but not PTEN.
format Online
Article
Text
id pubmed-4094901
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40949012014-07-15 Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples Stewart, David J Nunez, Maria I Jelinek, Jaroslav Hong, David Gupta, Sanjay Aldaz, Marcelo Issa, Jean-Pierre Kurzrock, Razelle Wistuba, Ignacio I Clin Epigenetics Research BACKGROUND: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTEN), immunohistochemistry scores from pre- and post-decitabine tumor biopsies (25 patients) were correlated with methylation of the long interspersed nuclear element-1 (LINE-1) repetitive DNA element (as a surrogate for global DNA methylation) and with tumor regression. RESULTS: With negative staining pre-decitabine (score = 0), the number of patients converting to positive staining post-decitabine was 1 of 1 for FHIT, 3 of 6 for WWOX, 2 of 3 for FUS1 and 1 of 10 for PTEN. In tumors with low pre-decitabine tumor suppressor gene scores (≤150), expression was higher post-treatment in 8 of 8 cases for FHIT (P = 0.014), 7 of 17 for WWOX (P = 0.0547), 7 of 12 for FUS1 (P = 0.0726), and 1 of 16 for PTEN (P = 0.2034). If FHIT, WWOX and FUS1 were considered together, median pre- versus post-decitabine scores were 60 versus 100 (P = 0.0002). Overall, tumor suppressor gene expression change did not correlate with LINE-1 demethylation, although tumors converting from negative to positive had a median decrease in LINE-1 methylation of 24%, compared to 6% in those not converting (P = 0.069). Five of 15 fully evaluable patients had reductions in tumor diameter (range 0.2% to 33.4%). Of these, three had simultaneous increases in three tumor suppressor genes (including the two patients with the greatest tumor regression) compared to 2 of 10 with tumor growth (P = 0.25). CONCLUSIONS: In tumors with low tumor suppressor gene expression, decitabine may be associated with increased expression of the tumor suppressor genes FHIT, FUS1, and WWOX, but not PTEN. BioMed Central 2014-07-03 /pmc/articles/PMC4094901/ /pubmed/25024751 http://dx.doi.org/10.1186/1868-7083-6-13 Text en Copyright © 2014 Stewart et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Stewart, David J
Nunez, Maria I
Jelinek, Jaroslav
Hong, David
Gupta, Sanjay
Aldaz, Marcelo
Issa, Jean-Pierre
Kurzrock, Razelle
Wistuba, Ignacio I
Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
title Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
title_full Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
title_fullStr Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
title_full_unstemmed Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
title_short Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
title_sort impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes fhit, wwox, fus1 and pten in clinical tumor samples
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094901/
https://www.ncbi.nlm.nih.gov/pubmed/25024751
http://dx.doi.org/10.1186/1868-7083-6-13
work_keys_str_mv AT stewartdavidj impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT nunezmariai impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT jelinekjaroslav impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT hongdavid impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT guptasanjay impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT aldazmarcelo impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT issajeanpierre impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT kurzrockrazelle impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples
AT wistubaignacioi impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples